Japanese Journal of Thrombosis and Hemostasis

Japanese Journal of Thrombosis and Hemostasis

Online ISSN : 1880-8808
Print ISSN : 0915-7441
ISSN-L : 0915-7441

Search

Search
Browse

All issues

Predecessor

Volume 20, Issue 3

Displaying 1-16 of 16 articles from this issue

Download citation

Show all abstracts

|<
<
1
>
>|

Thrombosis and Hemostasis in clinical medicine − practical guidance for residents

1. Coagulation factor products Immunoglobulin (Adjustment and directions of blood products transfusion)

Yoshiaki TOMIYAMA

2009 Volume 20 Issue 3 Pages 275-277
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.275

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (828K)
1. Systemic and local hemostatic agents (Hemostatic, the antifibrolytic agent's adjustment, and directions)

Mineji HAYAKAWA, Satoshi GANDO

2009 Volume 20 Issue 3 Pages 278-280
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.278

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (777K)
2. Drugs for hemostasis (Vitamin K and Protamine sulfate) (Hemostatic, the antifibrolytic agent's adjustment, and directions)

Yoshitaka MORI, Hideo WADA

2009 Volume 20 Issue 3 Pages 281-284
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.281

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (847K)
3. Antifibrinolytic treatment (Hemostatic, the antifibrolytic agent's adjustment, and directions)

Hidesaku ASAKURA, Tomoe HAYASHI

2009 Volume 20 Issue 3 Pages 285-288
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.285

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (990K)
4. DDAVP (Hemostatic, the antifibrolytic agent's adjustment, and directions)

Masaru SHIBATA

2009 Volume 20 Issue 3 Pages 289-291
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.289

JOURNAL FREE ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (867K)

Reviews

Stem cell therapy for hemophilia A

Yoshihiko SAKURAI

2009 Volume 20 Issue 3 Pages 292-300
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.292

JOURNAL FREE ACCESS

Download PDF (2806K)
MYH9 regulates proplatelet formation and platelet contraction

Shinji KUNISHIMA

2009 Volume 20 Issue 3 Pages 301-306
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.301

JOURNAL FREE ACCESS

Download PDF (962K)
Crystal structures of snake venom metalloproteinases and the molecular mechanism of factor X activation by Russell's viper venom

Soichi TAKEDA

2009 Volume 20 Issue 3 Pages 307-314
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.307

JOURNAL FREE ACCESS

Download PDF (1267K)

Original Articles

Effects of heme oxygenase-1 on tissue factor and thrombomodulin in the endothelial cell

Keiko MARUYAMA, Eriko MORISITA, Akiko SEKIYA, Satomi NAGAYA, Tadaaki K ...

2009 Volume 20 Issue 3 Pages 315-322
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.315

JOURNAL FREE ACCESS

Show abstractHide abstract

Heme oxygenases (HO) are rate-limiting enzymes that catalyze the conversion of heme into biliverdin, free iron and carbon monoxide. They exist in three different isoforms, HO-1, HO-2 and HO-3. Recently, Yachie et al. reported the first human case of HO-1 deficiency. In this child, both intravascular hemolysis and endothelial cell injury were prominent. In addition, abnormalities of coagulation/fibrinolysis system were marked. The aim of this study was to elucidate the effects of HO-1 or HO-1 products on expression of tissue factor (TF) and thrombomodulin (TM) in human endothelial cells (HUVEC), in vitro. HUVEC were incubated with either hemin (HO-1 inducer) or hemin/Tin protoporphyrin IX (SnPP, HO-1 inhibitor) at 37 °C for each hours. The levels of mRNA of HO-1, TF and TM were determined by real-time reverse transcriptase polymerase chain reaction. The levels of antigen of cell lysates were determined by ELISA. Hemin increased HO-1 and TM expression. On the other hand, hemin/SnPP increased TF expression and decreased TM expression. In conclusion, HO-1 or HO-1 products might regulate TF and TM expression and prevent thrombus formation in human endothelial cells.

View full abstract

Download PDF (838K)

Topics

Current state of research on intrinsic pathway of blood coagulation ; Factor XII, factor XI and high-molecular-weight kininogen deficient mice

Yasushi NAKATOMI, Tomohiro NAKAGAKI

2009 Volume 20 Issue 3 Pages 323-328
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.323

JOURNAL FREE ACCESS

Download PDF (859K)
Current status and limitation of thienopyridine antiplatelets

Yasuhiro NISHIKAWA

2009 Volume 20 Issue 3 Pages 329-335
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.329

JOURNAL FREE ACCESS

Show abstractHide abstract

The dual antiplatelet therapy of aspirin and clopidogrel is currently the standard therapy for patients with acute coronary syndrome (ACS). There has been accumulating evidence indicating presence of clopidogrel resistance or non-responders. Clopidogrel non-responders are associated with more ischemic events. Inhibition of platelet aggregation is reduced in non-responders. Because clopidogrel exhibits its antiplatelet effects through biotransformation to active metabolite by CYP2C19 in the liver, the reduced function of CYP2C19 is considered as the main reason for non-responders. This is supported by several observations that patients with CYP2C19 loss of function allele had more frequent ischemic events with reduced exposure to the active metabolite, and that more potent and consistent, a new antiplatelet agent, prasugrel, showed improved clinical outcomes compared with clopidogrel. There remains unclear whether or not antiplatelet strategy based on the genotyping or measurements of antiplatelet activity in each individual will improve clinical outcomes.

View full abstract

Download PDF (1346K)

Message

The Coagulation and Fibrinolysis Systems and Atherosclerosis (Impairment of the Coagulation-Fibrinolysis Systems Hypothesis on Atherosclerosis)

Kenzo TANAKA

2009 Volume 20 Issue 3 Pages 336-341
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.336

JOURNAL FREE ACCESS

Download PDF (844K)

Small talks on my research career

Platelet-derived microparticle (PDMP)

Shosaku NOMURA

2009 Volume 20 Issue 3 Pages 342-346
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.342

JOURNAL FREE ACCESS

Download PDF (837K)

The 2nd Daiichi-Sankyo Symposium for Thrombosis Update

1. New global fibrinolysis assays and their clinical application

Dingeman C. RIJKEN

2009 Volume 20 Issue 3 Pages 348-354
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.348

JOURNAL FREE ACCESS

Download PDF (1701K)
2. Sirolimus-Eluting Stent (SES) and antiplatelet therapy

Takeshi KIMURA

2009 Volume 20 Issue 3 Pages 355-359
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.355

JOURNAL FREE ACCESS

Download PDF (779K)
3. Diagnosis system PTX3 of the thrombus in the artery that appeared from the systematic antibody making from the genome

Tatsuhiko KODAMA

2009 Volume 20 Issue 3 Pages 360-366
Published: 2009
Released on J-STAGE: July 16, 2009

DOIhttps://doi.org/10.2491/jjsth.20.360

JOURNAL FREE ACCESS

Download PDF (1330K)

|<
<
1
>
>|

Top